Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Diasome Pharmaceuticals, Inc. is developing hepatocyte directed vesicle (HDV) technology, an insulin additive, to lessen the instances of high and low blood sugar levels in people with diabetes to improve disease management and quality of life. HDV may improve the safety and efficacy of any commercially available insulin by restoring the liver’s natural role in blood glucose control.

List your booth number for exhibitions, ask us